Published in Sex Transm Dis on October 01, 2003
Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: joint European cohort study. BMJ (2008) 4.77
Prevalence of papillomavirus infection in women in Ibadan, Nigeria: a population-based study. Br J Cancer (2004) 2.33
Human papillomavirus infection in Shanxi Province, People's Republic of China: a population-based study. Br J Cancer (2006) 1.83
Papillomavirus infection in rural women in southern India. Br J Cancer (2005) 1.79
Human papillomavirus and HPV vaccines: a review. Bull World Health Organ (2007) 1.55
Concordance of prevalence of human papillomavirus DNA in anogenital and oral infections in a high-risk population. J Clin Microbiol (2004) 1.34
Age-dependent prevalence of 14 high-risk HPV types in the Netherlands: implications for prophylactic vaccination and screening. Br J Cancer (2008) 1.16
HPV type-specific prevalence using a urine assay in unvaccinated male and female 11- to 18-year olds in Scotland. Br J Cancer (2011) 1.11
Prevalence of human papillomavirus infection in women in Benin, West Africa. Virol J (2011) 1.08
Prevalence and type distribution of human papillomavirus in 5,000 British Columbia women--implications for vaccination. Cancer Causes Control (2009) 1.07
Cervical human papillomavirus infection in accra, ghana. Ghana Med J (2008) 0.99
Prevalence and risk factors of Human Papillomavirus (HPV) infection in southern Chinese women - a population-based study. PLoS One (2011) 0.96
Differences in the risk of cervical cancer and human papillomavirus infection by education level. Br J Cancer (2009) 0.95
Prevalence of human papillomavirus genotypes and their variants in high risk West Africa women immigrants in South Italy. Infect Agent Cancer (2007) 0.92
Oncogenic human papillomavirus (HPV) type distribution and HPV type 16 E6 variants in two Spanish population groups with different levels of HPV infection risk. J Clin Microbiol (2006) 0.92
Human papillomavirus infections in women seeking cervical Papanicolaou cytology of Durango, Mexico: prevalence and genotypes. BMC Infect Dis (2006) 0.91
Trends in oral cavity, pharyngeal, oesophageal and gastric cancer mortality rates in Spain, 1952-2006: an age-period-cohort analysis. BMC Cancer (2014) 0.91
Higher prevalence of human papillomavirus infection in migrant women from Latin America in Spain. Sex Transm Infect (2006) 0.90
Difference in overall and age-specific prevalence of high-risk human papillomavirus infection in Italy: evidence from NTCC trial. BMC Infect Dis (2013) 0.90
Determinants of newly detected human papillomavirus infection in HIV-infected and HIV-uninfected injection drug using women. Sex Transm Dis (2009) 0.87
Prevalence of HPV infection among Greek women attending a gynecological outpatient clinic. BMC Infect Dis (2010) 0.86
Human Papillomavirus (HPV) Type Distribution in Females with Abnormal Cervical Cytology. A Correlation with Histological Study. Open Virol J (2009) 0.86
Human papillomavirus genotype distribution in Madrid and correlation with cytological data. BMC Infect Dis (2011) 0.85
Human papillomavirus infection: an anonymous prevalence study in South Wales, UK. Br J Cancer (2006) 0.84
Predictors of human papillomavirus infection in women undergoing routine cervical cancer screening in Spain: the CLEOPATRE study. BMC Infect Dis (2012) 0.83
Genotype distribution of human papillomavirus (HPV) in histological sections of cervical intraepithelial neoplasia and invasive cervical carcinoma in Madrid, Spain. BMC Cancer (2012) 0.80
The impact of smoking on HPV infection and the development of anogenital warts. Int J Colorectal Dis (2014) 0.79
Socio-economic and cultural vulnerabilities to cervical cancer and challenges faced by patients attending care at Tikur Anbessa Hospital: a cross sectional and qualitative study. BMC Womens Health (2015) 0.78
Marijuana use is not associated with cervical human papillomavirus natural history or cervical neoplasia in HIV-seropositive or HIV-seronegative women. Cancer Epidemiol Biomarkers Prev (2010) 0.76
Prevalence of human papillomavirus in university young women. Oncol Lett (2011) 0.75
HPV and cofactors for invasive cervical cancer in Morocco: a multicentre case-control study. BMC Cancer (2017) 0.75
Six years genotype distribution of Human Papillomavirus in Calabria Region, Southern Italy: a retrospective study. Infect Agent Cancer (2017) 0.75
Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med (2003) 31.67
WHO-EORTC classification for cutaneous lymphomas. Blood (2005) 12.14
Male circumcision, penile human papillomavirus infection, and cervical cancer in female partners. N Engl J Med (2002) 10.80
Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol (2010) 9.86
Against which human papillomavirus types shall we vaccinate and screen? The international perspective. Int J Cancer (2004) 6.99
Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis. Lancet Infect Dis (2007) 6.86
Human papillomavirus and oral cancer: the International Agency for Research on Cancer multicenter study. J Natl Cancer Inst (2003) 6.28
Overview of the European and North American studies on HPV testing in primary cervical cancer screening. Int J Cancer (2006) 5.87
GP5+/6+ PCR followed by reverse line blot analysis enables rapid and high-throughput identification of human papillomavirus genotypes. J Clin Microbiol (2002) 5.63
Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol (2011) 5.57
Human papillomavirus type distribution in 30,848 invasive cervical cancers worldwide: Variation by geographical region, histological type and year of publication. Int J Cancer (2011) 5.43
Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer. Nat Genet (2012) 5.28
14-day triple, 5-day concomitant, and 10-day sequential therapies for Helicobacter pylori infection in seven Latin American sites: a randomised trial. Lancet (2011) 5.21
The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years. J Infect Dis (2009) 5.09
Effect of oral contraceptives on risk of cervical cancer in women with human papillomavirus infection: the IARC multicentric case-control study. Lancet (2002) 5.00
Efficacy of fewer than three doses of an HPV-16/18 AS04-adjuvanted vaccine: combined analysis of data from the Costa Rica Vaccine and PATRICIA trials. Lancet Oncol (2015) 4.84
Overview of human papillomavirus-based and other novel options for cervical cancer screening in developed and developing countries. Vaccine (2008) 4.82
Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: joint European cohort study. BMJ (2008) 4.77
The carcinogenicity of human papillomavirus types reflects viral evolution. Virology (2005) 4.72
Effect of human papillomavirus 16/18 L1 viruslike particle vaccine among young women with preexisting infection: a randomized trial. JAMA (2007) 4.66
Alcohol drinking in never users of tobacco, cigarette smoking in never drinkers, and the risk of head and neck cancer: pooled analysis in the International Head and Neck Cancer Epidemiology Consortium. J Natl Cancer Inst (2007) 4.55
Cervical human papillomavirus prevalence in 5 continents: meta-analysis of 1 million women with normal cytological findings. J Infect Dis (2010) 4.42
Epidemiology and natural history of human papillomavirus infections and type-specific implications in cervical neoplasia. Vaccine (2008) 4.31
A novel algorithm for reliable detection of human papillomavirus in paraffin embedded head and neck cancer specimen. Int J Cancer (2007) 4.29
Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women. J Natl Cancer Inst (2010) 4.20
Worldwide human papillomavirus etiology of cervical adenocarcinoma and its cofactors: implications for screening and prevention. J Natl Cancer Inst (2006) 4.14
Genetic variation in TNF and IL10 and risk of non-Hodgkin lymphoma: a report from the InterLymph Consortium. Lancet Oncol (2006) 4.13
Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol (2011) 3.98
Role of parity and human papillomavirus in cervical cancer: the IARC multicentric case-control study. Lancet (2002) 3.96
Longitudinal study of human papillomavirus persistence and cervical intraepithelial neoplasia grade 2/3: critical role of duration of infection. J Natl Cancer Inst (2010) 3.95
Proof-of-principle evaluation of the efficacy of fewer than three doses of a bivalent HPV16/18 vaccine. J Natl Cancer Inst (2011) 3.92
Chapter 3: HPV type-distribution in women with and without cervical neoplastic diseases. Vaccine (2006) 3.72
Genetic patterns in head and neck cancers that contain or lack transcriptionally active human papillomavirus. J Natl Cancer Inst (2004) 3.67
Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years and older. Int J Cancer (2009) 3.64
Human papillomavirus testing for the detection of high-grade cervical intraepithelial neoplasia and cancer: final results of the POBASCAM randomised controlled trial. Lancet Oncol (2011) 3.58
The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in sexually active women aged 16-26 years. J Infect Dis (2009) 3.55
Comparisons of HPV DNA detection by MY09/11 PCR methods. J Med Virol (2002) 3.53
A prospective study of age trends in cervical human papillomavirus acquisition and persistence in Guanacaste, Costa Rica. J Infect Dis (2005) 3.46
Human papillomavirus infection with multiple types: pattern of coinfection and risk of cervical disease. J Infect Dis (2011) 3.44
Variations in the age-specific curves of human papillomavirus prevalence in women worldwide. Int J Cancer (2006) 3.38
Interaction between tobacco and alcohol use and the risk of head and neck cancer: pooled analysis in the International Head and Neck Cancer Epidemiology Consortium. Cancer Epidemiol Biomarkers Prev (2009) 3.33
Rapid clearance of human papillomavirus and implications for clinical focus on persistent infections. J Natl Cancer Inst (2008) 3.32
Chapter 9: Clinical applications of HPV testing: a summary of meta-analyses. Vaccine (2006) 3.15
Bead-based multiplex genotyping of human papillomaviruses. J Clin Microbiol (2006) 3.13
Projected clinical benefits and cost-effectiveness of a human papillomavirus 16/18 vaccine. J Natl Cancer Inst (2004) 3.11
Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer. Vaccine (2012) 3.09
POBASCAM, a population-based randomized controlled trial for implementation of high-risk HPV testing in cervical screening: design, methods and baseline data of 44,102 women. Int J Cancer (2004) 2.89
Chapter 3: Cofactors in human papillomavirus carcinogenesis--role of parity, oral contraceptives, and tobacco smoking. J Natl Cancer Inst Monogr (2003) 2.87
Efficacy of a bivalent HPV 16/18 vaccine against anal HPV 16/18 infection among young women: a nested analysis within the Costa Rica Vaccine Trial. Lancet Oncol (2011) 2.85
Subcutaneous panniculitis-like T-cell lymphoma: definition, classification, and prognostic factors: an EORTC Cutaneous Lymphoma Group Study of 83 cases. Blood (2007) 2.82
Epidemiological study of anti-HPV16/18 seropositivity and subsequent risk of HPV16 and -18 infections. J Natl Cancer Inst (2010) 2.81
Herpes simplex virus-2 as a human papillomavirus cofactor in the etiology of invasive cervical cancer. J Natl Cancer Inst (2002) 2.75
Short term persistence of human papillomavirus and risk of cervical precancer and cancer: population based cohort study. BMJ (2009) 2.68
A study of the impact of adding HPV types to cervical cancer screening and triage tests. J Natl Cancer Inst (2005) 2.60
Intrauterine device use, cervical infection with human papillomavirus, and risk of cervical cancer: a pooled analysis of 26 epidemiological studies. Lancet Oncol (2011) 2.52